(Reuters) - Emergent BioSolutions Inc (N:EBS) said on Monday it signed a $174 million (135 million pounds) agreement with AstraZeneca (L:AZN) to develop and manufacture the British drugmaker's COVID-19 vaccine candidate.
AstraZeneca in June picked Emergent to help produce the 300 million doses of its potential COVID-19 vaccine pledged to the United States.